The Grayson-Jockey Club Research Foundation has issued a formal call for applications for research focused on the development of a nucleic acid-based vaccine against Equine Herpes Virus (EHV). Dr. John Ballantyne and the Fargo-Moorhead Area Foundation have committed $2 million to fund this research.
“We are very grateful to Dr. Ballantyne for his generosity in supporting efforts to combat EHV, a disease that affects all horses,” said Dell Hancock, president of the foundation. “This gift will allow Grayson to continue its commitment to funding critical research for horses, and our Research Advisory Board looks forward to seeing what proposals will be submitted.”
“As a horse owner with a background in biotechnology, I recognize the danger of EHV and see the potential for nucleic acid vaccines to combat this disease,” said Dr Ballantyne. “I am proud to work with Grayson to support EHV research.”
Grayson is interested in research proposals focused on EHV-1, EHV-3 and EHV-4, with a multivalent or panvalent approach. Researchers must have the ability to conduct a live proof of principle of effectiveness in the equine model internally or in collaboration. Applications from established equine researchers collaborating with experts from other fields (e.g., human vaccinologists) are strongly encouraged. It is anticipated that this research will span three to four years and possibly multiple projects.
Grant applications are due October 1, 2022 and can be submitted to grayson-jockeyclub.org.
The Grayson-Jockey Club Research Foundation has traditionally been the nation’s primary source of private funding for equine medical research that benefits all breeds of horses. Since 1983, the foundation has provided more than $30.6 million to fund 397 projects at 45 universities in North America and abroad. Further information on the foundation is available atgrayson-jockeyclub.org.